ReviewAdvanced drug delivery reviews2020
Membrane-core nanoparticles for cancer nanomedicine.
Review in Advanced drug delivery reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 66 citations in OpenAlex.
- A sequentially programmed FeMaterials today. Bio · 2026Article
- Cancer Therapy with Polymeric Nanocarriers and the Transition to Targeted Cancer Therapy: Advances and Future Directions.Pharmaceutical nanotechnology · 2026Review
- Nanodelivery of panobinostat induces cell cycle arrest and apoptosis to suppress hepatocellular carcinoma growth in mice.Materials today. Bio · 2025Article
- Lenalidomide promotes melarsoprol-activated cGAS-STING-mediated immunotherapy for hepatocellular carcinomaFundamental research · 2025Article
- Nanocatalytic system releases overloaded zinc ions and ROS to induce Znproptosis and interrupt cell cycle through inhibiting Akt/mTOR pathway.Theranostics · 2025Review
- Activation of the cGAS-sting Pathway Mediated by Nanocomplexes for Tumor Therapy.Current pharmaceutical design · 2025Review
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- Enhanced Efficacy against Drug-Resistant Tumors Enabled by Redox-Responsive Mesoporous-Silica-Nanoparticle-Supported Lipid Bilayers as Targeted Delivery Vehicles.International journal of molecular sciences · 2024Article
- d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma.Science advances · 2023Article
- Bionic natural small molecule co-assemblies towards targeted and synergistic Chemo/PDT/CDT.Biomaterials research · 2023Article
- Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors.Frontiers in immunology · 2023Review
- Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles.Scientific reports · 2022Article
- Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.Vaccines · 2022Review
- Tumor-Activatable Nanoparticles Target Low-Density Lipoprotein Receptor to Enhance Drug Delivery and Antitumor Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.Acta pharmaceutica Sinica. B · 2022Article
- Recent Progress of Novel Nanotechnology Challenging the Multidrug Resistance of Cancer.Frontiers in pharmacology · 2022Review
- Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Targeting Engineered Nanoparticles for Breast Cancer Therapy.Pharmaceutics · 2021Review
- Delivery of cancer therapies by synthetic and bio-inspired nanovectors.Molecular cancer · 2021Review
- Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.Molecular cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Cancer is one of the most severe disease burdens in modern times, with an estimated increase in the number of patients diagnosed globally from 18.1 million in 2018 to 23.6 million in 2030. Despite a significant progress achieved by conventional therapies, they have limitations and are still far from ideal. Therefore, safe, effective and widely-applicable treatments are urgently needed. Over the past decades, the development of novel delivery approaches based on membrane-core (MC) nanostructures for transporting chemotherapeutics, nucleic acids and immunomodulators has significantly improved anticancer efficacy and reduced side effects. In this review, the formulation strategies based on MC nanostructures for delivery of anticancer drug are described, and recent advances in the application of MC nanoformulations to overcome the delivery hurdles for clinical translation are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.